News Quantified

VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)

Vertex Pharmaceuticals (VRTX) was given a new $612.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.

4/8

10:38 pm

vrtx

Low

Vertex Pharmaceuticals (VRTX) Valuation Check After FDA Expands ALYFTREK And TRIKAFTA Use [Yahoo! Finance]

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]

Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand [Seeking Alpha]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}